68
Markets3h 44m ago

Dyadic's C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets.

Archive Window: 7 Days Left

Jupiter, Florida

Who
Dyadic International, Inc.; Mark A. Emalfarb; Scripps Research; CEPI; Fondazione Biotecnopolo di Siena; European Vaccines Hub
What
Dyadic's C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets.
When
Mon, 15 Jun 2026 11:28:03 GMT · 3h 44m ago
Where
Jupiter, Florida ·
Why
Dyadic highlighted increasing interest in its proprietary C1 protein production platform as global infectious disease preparedness efforts intensify in response to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and as the Company continues to advance commercial adoption across multiple high-growth markets.
The Frontline Impact

How this affects you

The ongoing Bundibugyo Ebola virus outbreak underscores a critical need for rapid vaccine and antibody production, highlighting Dyadic's C1 platform as a potential solution for accelerating global health responses and expanding commercial products in life sciences, food, and industrial sectors.

Story chain

3 events in this thread

Verified Sources & Citations